LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC

The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.

Related Keywords

Munich ,Bayern ,Germany ,Gauting ,Daiichi Sankyo ,Niels Reinmuth ,Pfizer ,Amgen ,Boehringer Ingelheim ,Speaker Bureau For Amgen ,Oncology Congress ,Astrazeneca ,Thoracic Oncology Department ,Bristol Myers Squibb ,Asklepios Lung Clinic ,Hoffman La Roche ,Published March ,Platinum Etoposide And Concurrent Durvalumab ,Patients With Extensive Stage Small Cell Lung Cancer ,Luminance Study ,Caspian Trial ,Nct04774380 ,Nct03043872 ,D ,Phd ,